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Abstract
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a predictor of cardiovascular events that has
been shown to vary with race. The objective of this study was to examine factors associated with this racial
variation.
Methods: We measured Lp-PLA2 mass and activity in 714 healthy older adults with no clinical coronary heart
disease and not taking dyslipidemia medication. We evaluated the association between race and Lp-PLA2 mass and
activity levels after adjustment for various covariates using multivariable linear regression. These covariates included
age, sex, diabetes, hypertension, body mass index, lipid measurements, C-reactive protein, smoking status, physical
activity, diet, income, and education level. We further examined genetic covariates that included three single
nucleotide polymorphisms shown to be associated with Lp-PLA2 activity levels.
Results: The mean age was 66 years. Whites had the highest Lp-PLA2 mass and activity levels, followed by
Hispanics and Asians, and then African-Americans; in age and sex adjusted analyses, these differences were
significant for each non-White race as compared to Whites (p < 0.0001). For example, African-Americans were
predicted to have a 55.0 ng/ml lower Lp-PLA2 mass and 24.7 nmol/ml-min lower activity, compared with Whites,
independent of age and sex (p < 0.0001). After adjustment for all covariates, race remained significantly correlated
with Lp-PLA2 mass and activity levels (p < 0.001) with African-Americans having 44.8 ng/ml lower Lp-PLA2 mass
and 17.3 nmol/ml-min lower activity compared with Whites (p < 0.0001).
Conclusion: Biological, lifestyle, demographic, and select genetic factors do not appear to explain variations in Lp-
PLA2 mass and activity levels between Whites and non-Whites, suggesting that Lp-PLA2 mass and activity levels
may need to be interpreted differently for various races.
Background
Lipoprotein-associated phospholipase A2 (Lp-PLA2)
circulates in the blood as an enzyme bound mainly to
low-density lipoprotein (LDL) particles. Lp-PLA2 has
been found in multiple studies to be associated with
incident and prevalent coronary heart disease (CHD)
[1-6] and incident stroke,[5,7] independent of standard
cardiovascular risk factors[8]. A collaborative meta-
analysis of 32 prospective studies in 79,000 patients
showed that both Lp-PLA2 mass and activity added
predictive value for vascular events and mortality
beyond traditional cardiovascular risk factors[9]. Cur-
rently, a direct Lp-PLA2 inhibitor is being tested in a
randomized trial for prevention of cardiovascular
events in patients with CHD[10]. In a study of the gen-
eral population, Lp-PLA2 mass and activity levels were
higher in Whites compared with African-Americans or
Hispanics[11]. However, the degree to which genetic
differences as opposed to lifestyle variations, including
smoking status, diet and exercise, may explain racial
differences remains unclear. The goals of this study
were to confirm the racial variations in Lp-PLA2 mass
and activity levels and to examine the factors that
might explain these racial differences in a multi-racial
cohort of healthy older individuals free of clinical CHD
and not taking dyslipidemia medications.
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Methods
Study Sample
The participants in this study were recruited from Kaiser
Permanente Northern California, a large integrated
healthcare system that provides comprehensive care to
more than 3 million people in San Francisco and the
greater Bay Area. Details of participant recruitment have
been described previously[12,13]. Briefly, we enrolled
adults between 60 and 72 years old who lived within
50 miles of the research facility, and who did not have a
diagnosis of cardiovascular disease, cancer, end-stage
renal disease, liver failure, dementia, or human immuno-
deficiency virus infection. By January 2001, 3,054 appar-
ently eligible subjects were randomly chosen to be sent
letters inviting participation. From these invitations, a
total of 1,024 subjects were recruited, consisting of 639
men and 385 women. In the final year of recruitment,
men, Hispanics, and African-Americans were selectively
oversampled in order to better match the cases enrolled
in the Atherosclerotic Disease, Vascular Function, and
Genetic Epidemiology study[14]. After excluding people
who were taking dyslipidemia medications from this ana-
lysis, 714 subjects were included in the study. The study
protocol was reviewed and approved annually by the
institutional review boards at both Stanford University
and the Division of Research at Kaiser Permanente
Northern California. Written informed consent was
obtained from all participants.
Risk Factor Measurement
All the study subjects attended a research clinic visit at
Stanford University and completed a health survey about
medical diagnoses, medication use, smoking history, family
history, race and ethnicity, dietary intake, and physical
activity. Subjects were asked to bring their medications,
which were independently reviewed and recorded by the
interviewer. Resting blood pressure was determined using
standard sphygmomanometers. Weight, height, and waist
circumference were measured by trained and certified staff
using a stadiometer, balance scale, and tape. Blood tests
were drawn for biomarker analysis, which included fasting
lipid levels, glucose, C-reactive protein,[15] and Lp-PLA2
mass and activity levels[16,17].
Stanford Seven-Day Physical Activity Recall
The Stanford Seven-Day Physical Activity Recall, a semi-
structured interview, was used to estimate the amount
of time that a person engaged in moderate-, hard-, and
very hard-intensity activities during the previous seven
days[18,19]. A trained interviewer guided the subject
through the recall process, day-by-day, to determine the
duration and intensity of physical activities performed,
as well as time spent sleeping[19]. Time spent in light
activity was estimated by subtracting the time included
in sleep and moderate-, hard-, and very hard-intensity
activities from the total hours in the recall period. Total
energy expenditure was estimated by multiplying the
hours spent in each level of activity with the estimated
energy expenditure value for each intensity category.
Block Food Frequency Questionnaire
The Block Food Frequency Questionnaire was used to
characterize dietary intake[20]. It queries average con-
sumption of 106 foods by portion size and includes 13
questions on dietary supplementation, six questions on
restaurant eating, five summary questions, eight ques-
tions on fat use or low-fat foods, and seven demo-
graphic and health-related questions.
Race Determination
Self-reported race was collected during the eligibility
screening survey, on the baseline health survey and from
the Kaiser Permanente data sources. In addition, birth-
place, grandparents’ race, and grandparents’ country of
origin were collected. The algorithm for assigning race
was as follows: if self-reported race and grandparents’
race were concordant, then subjects were coded to that
race category (> 80% of subjects). In discordant cases,
race was assigned by a hierarchy of grandparents’ race,
grandparents’ country of origin, self reported race on the
baseline health survey, and self-reported race on the
screening survey. Only the major racial groups of White,
African-American, Hispanic and Asian are used for this
analysis. This method of classifying race has been vali-
dated in this cohort by high-throughput genotyping of
more than 450,000 single nucleotide polymorphisms
(SNPs) among African-Americans and Whites[21].
Lp-PLA2 Measurement
Blood samples were collected at the baseline visit after an
overnight fast and stored in aliquots frozen at -80 °C. Lp-
PLA2 mass (ng/ml) was measured using a dual enzyme
linked immunoassay (PLAC test, diaDexus Inc., South San
Francisco, CA)[16]. Intra- and inter-assay coefficients of
variation were < 5% and < 8%, respectively, and sensitivity
across the assay range was < 0.5 ng/mL. Lp-PLA2 activity
(nmol/ml-min) was measured by a colorimetric activity
method (CAM test)[17]. Intra- and inter-assay coefficients
of variation were < 4% and < 6%, respectively, and sensitiv-
ity across the assay range was < 5 nmol/ml-min.
Single Nucleotide Polymorphism Selection
A literature search for all of the documented SNPs
related to Lp-PLA2 mass and activity levels was con-
ducted. Only those SNPs that were both documented in
the literature to be related to Lp-PLA2 and existed in
our database were included in the analysis. The SNPs
included in our database were selected for likely
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association with atherosclerosis as determined a priori
from literature review and by comparing up and down-
regulated genes in diseased and non-diseased vascular
endothelium. The genetic covariates included three
SNPs in the PLA2G7 locus (Lp-PLA2 gene) that have
been documented to be associated with Lp-PLA2 activ-
ity: Ala379Val (rs1051931), Arg92His (rs1805017), and
Ile198Thr (rs1805017)[22]. The SNPs were coded as 0
for homozygous major, 1 for heterozygous, and 2 for
homozygous minor.
Statistical methods
Baseline characteristics were presented as means and
standard deviations for normally distributed continuous
variables and as counts and proportions for categorical
variables. Medians and interquartile ranges were used
for non-normally distributed continuous variables. Dif-
ferences in the baseline variables between racial groups
were compared using a general linear model analysis of
variance (ANOVA).
Linear regression was used to examine the association
between race and Lp-PLA2 mass and activity in separate
models. The covariates for multivariable analysis were
selected a priori and included biological, lifestyle, demo-
graphic, and genetic characteristics. The biological covari-
ates included age, race, history of diabetes mellitus, history
of hypertension, quantitative systolic blood pressure mea-
surement, body mass index (BMI), waist circumference,
LDL cholesterol level, high density lipoprotein (HDL) cho-
lesterol level, asymmetric dimethylarginine (ADMA), and
C-reactive protein (CRP); the lifestyle and demographic
covariates were current smoking status, physical activity,
percent of calories from saturated fat, percent of calories
from carbohydrates, education level, and income.
A simple linear regression model was first used to ana-
lyze the relation between race and Lp-PLA2 mass and
activity adjusted for only sex. The biological, lifestyle, and
genetic covariates were each included in separate multi-
variable models in addition to a single multivariable model
with all the covariates. Data were analyzed using SAS, ver-
sion 9.1 (SAS Institute, Cary, North Carolina).
Results
The study population consisted of 540 whites, 60 Afri-
can-Americans, 62 Hispanics, and 52 Asians (Table 1).
The average age was 66 years and women comprised
40% of the study cohort. The prevalence of hyperten-
sion (62%) was slightly higher and the prevalence of
diabetes (13%) relatively lower than the general popu-
lation[23,24]. Mean LDL levels were mildly elevated
(128 mg/dL), while mean HDL levels were relatively
high (54 mg/dL). The cohort was overweight (mean
BMI of 28 kg/m2) and only a small proportion were
active smokers (7.3%).
Some baseline characteristics differed significantly
among the racial groups (Table 1). The study had insuffi-
cient power to compare the non-White racial groups to
each other, so all statistical comparisons are to Whites.
Whites were the least likely to be diabetic, while in com-
parison, African-Americans were the most likely to be dia-
betic. Asians had the lowest mean BMI and smallest mean
waist circumference. Asians and Hispanics were signifi-
cantly less likely to be actively smoking as compared with
Whites. Asians had a lower dietary intake of saturated fat
and higher intake of from carbohydrates (both as percent
of total energy). LDL and HDL levels were relatively simi-
lar comparing White with non-White groups. There were
also significant differences in the SNP frequencies between
White and non-White races. Compared with African-
Americans and Hispanics, Whites were more likely to
have the Ala379Val SNP. Hispanics were the most likely
to have the Arg92His SNP, while African-Americans were
the most likely to have the Ile198Thr SNP compared to
Whites.
Men had significantly higher Lp-PLA2 mass and activity
levels than women, after adjusting for all covariates (p =
0.025). The mean Lp-PLA2 mass for men was 246 ng/ml
compared with 223 ng/ml for women. The mean Lp-PLA2
activity for men was 142 nmol/ml-min compared with 114
nmol/ml-min for women. There was no evidence of an
interaction between sex and racial variations in Lp-PLA2
mass or activity in any model, so analyses were conducted
in the combined cohort of men and women. A secondary
analysis, which included subjects taking dyslipidemia med-
ications, showed the same overall findings and confirmed
that excluding these patients did not significantly change
the final results.
Lp-PLA2 mass and activity levels varied significantly
between Whites and non-Whites in all linear regression
models (Figures 1 and 2 and Tables 2 and 3). Whites had
the highest Lp-PLA2 mass and activity levels, followed by
Hispanics. African-Americans and Asians had the lowest
Lp-PLA2 mass and activity levels. These differences
between Whites and non-Whites remained highly signifi-
cant even after adjusting for all covariates. In fact, the
values of the b coefficients for non-White races were high,
ranging from -25 to -55 ng/ml across models for predict-
ing Lp-PLA2 mass and -10 to -28 nmol/ml-min for pre-
dicting Lp-PLA2 activity. The other covariates with strong
associations with Lp-PLA2 mass and activity levels
included age, LDL, HDL, and ADMA levels. The Arg92His
SNP in the PLA2G7 locus was associated with lower Lp-
PLA2 activity, but higher Lp-PLA2 mass, whereas the
other two SNPs had no significant associations.
None of the other covariates were consistently asso-
ciated with Lp-PLA2 mass and activity levels. Hyperten-
sion and diabetes were weakly associated with Lp-PLA2
activity and not associated with mass. Conversely,
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C-reactive protein was weakly associated with Lp-PLA2
mass, but not activity. None of the lifestyle covariates
were significantly associated with Lp-PLA2 mass or
activity levels.
Discussion
Our study confirms that Lp-PLA2 mass and activity
levels vary significantly between White and non-White
races in healthy older adults without clinically diagnosed
CHD and not taking dyslipidemia medications. Whites
have the highest Lp-PLA2 mass and activity levels, His-
panics have intermediate levels, and African-Americans
and Asians have the lowest Lp-PLA2 mass and activity
levels. These relationships were not affected by statistical
adjustment for lifestyle and demographic factors, stan-
dard biological risk factors, and three SNPs known to be
associated with Lp-PLA2 activity levels. These findings
suggest that differences in Lp -PLA2 mass and activity
levels between Whites and non-Whites may be due to
other genetic factors or perhaps to unmeasured lifestyle
factors.
The differences between White, Hispanic, and Afri-
can-American race and Lp-PLA2 mass and activity
levels in our study were similar to the results from the
Dallas Heart Study, the largest community-based study
of Lp-PLA2 levels[11]. One key difference was that our
Table 1 Baseline characteristics among older adults without clinical cardiovascular disease by major race subgroups;
mean (s.d.) and N (%)
Variable All subjects White African- American Hispanic Asian P-value*
(n = 714) (n = 540) (n = 60) (n = 62) (n = 52)
Age (years) 65.8 (2.9) 65.7 (2.9) 65.5 (3.0) 66.3 (2.8) 65.9 (2.5) 0.38
Female gender 284 (40%) 216 (40%) 20 (33%) 26 (42%) 22 (42%) 0.73
Diabetes mellitus 91 (13%) 58 (11%) 15 (25%) 10 (16%) 8 (15%) 0.011
History of hypertension 440 (62%) 321 (59%) 45 (75%) 39 (63%) 35 (67%) 0.095
Systolic blood pressure (mmHg) 131 (18) 130 (17) 136 (22) 133 (15) 136 (20) 0.0045
Body mass index (kg/m2) 27.9 (5.0) 27.8 (5.0) 30.3 (5.8) 28.9 (3.9) 25.4 (3.6) < 0.0001
Waist circumference (cm) 93.0 (14.6) 92.9 (14.4) 98.8 (16.9) 95.2 (12.9) 84.4 (11.4) < 0.0001
Low density lipoprotein (mg/dL) 128 (32) 128 (30) 125 (38) 125 (32) 128 (36) 0.78
High density lipoprotein (mg/dL) 54 (16) 55 (17) 56 (17) 53 (15) 53 (13) 0.61
Triglycerides (mg/dL)† 116 (86) 118 (84) 97 (64) 138 (113) 121 (89) 0.12
ADMA‡ (μmol/L) 0.63 (0.10) 0.64 (0.11) 0.61 (0.10) 0.64 (0.09) 0.62 (0.09) 0.20
C-reactive protein (mg/L) 3.4 (6.4) 3.4 (6.7) 4.4 (6.6) 3.5 (5.1) 1.9 (2.8) 0.22
LpPLA2 mass (ng/mL)
† 227 (71) 233 (75) 198 (63) 221 (59) 202 (73) < 0.0001
LpPLA2 activity (nmol/ml-min)
† 130 (43) 134 (41) 108 (32) 124 (36) 124 (61) < 0.0001
LpPLA2 mass > 235 ng/mL 302 (42%) 260 (48%) 11 (18%) 19 (31%) 12 (24%) < 0.0001
Current cigarette smoking 52 (7.3%) 42 (7.8%) 8 (13.3%) 1 (1.6%) 1 (1.9%) 0.035
Physical activity (kCal/kg-day) 34.8 (3.5) 34.9 (3.6) 34.4 (3.7) 35.0 (3.1) 34.6 (2.8) 0.76
Percent of calories from saturated fat 10.1 (2.7) 10.3 (2.7) 10.3 (2.9) 10.1 (2.5) 8.5 (1.7) 0.0001
Percent of calories from carbohydrates 46.6 (9.1) 46.0 (9.0) 46.3 (9.1) 49.1 (9.7) 49.8 (8.2) 0.0038
Annual income ≥ $50,000 452 (68%) 351 (70%) 37 (70%) 30 (54%) 34 (68%) 0.11
College graduate 173 (17%) 133 (25%) 10 (17%) 9 (15%) 21 (40%) 0.0059
Ala379Val
Homozygous major 440 (63%) 340 (64%) 29 (49%) 32 (52%) 39 (75%) 0.011
Heterozygous 235 (33%) 170 (32%) 28 (47%) 25 (41%) 12 (23%) 0.021
Homozygous minor 28 (4%) 21 (4%) 2 (3%) 4 (7%) 1 (2%) 0.64
Arg92His
Homozygous major 394 (56%) 291 (55%) 39 (66%) 27 (44%) 37 (71%) 0.011
Heterozygous 256 (36%) 198 (37%) 17 (29%) 28 (46%) 13 (25%) 0.075
Homozygous minor 55 (8%) 44 (8%) 3 (5%) 6 (10%) 2 (4%) 0.52
Ile198Thr
Homozygous major 617 (87%) 479 (90%) 36 (61%) 59 (97%) 43 (83%) < 0.0001
Heterozygous 85 (12%) 52 (10%) 22 (37%) 2 (3%) 9 (17%) < 0.0001
Homozygous minor 4 (0.6%) 3 (0.6%) 1 (2%) 0 (0%) 0 (0%) 0.58
* P-value indicates the comparison across racial groups by ANOVA
† Median (interquartile range), ‡ ADMA, asymmetric dimethylarginine
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study also included Asians, who were found to have
Lp-PLA2 mass and activity levels that were similar to
African-Americans, but lower than Whites. Our study
also demonstrated that racial differences in Lp-PLA2
mass and activity levels apply to older adults, given the
fact that individuals in our study (mean age of 66 years)
were substantially older than those in the Dallas Heart
Study (mean age of 45 years). The Dallas Heart Study
cohort included individuals taking statin medication,
whereas our study excluded individuals taking any dysli-
pidemia medication, because such medications may
reduce Lp-PLA2 mass and activity levels[25]. Other stu-
dies that were in a small cohort[26] and in a selected
population with vascular disease[27] also showed that
Whites have higher Lp-PLA2 mass and activity levels as
compared with other races.
Because Lp-PLA2 circulates bound to LDL particles,
Lp-PLA2 mass and activity levels depend greatly upon
lipid metabolism and are strongly association with LDL
and HDL levels[16]. Although we also found this asso-
ciation, adjustment for LDL and HDL levels did not
alter the relation between race and Lp-PLA2 mass and
activity levels, suggesting that variations in LDL and
HDL levels do not explain these racial differences. Diet
and physical activity also affect lipid metabolism,[28] but
adjustment for these lifestyle factors did not attenuate
the association between race and Lp-PLA2 mass and
activity levels.
Various studies have shown associations between Lp-
PLA2 mass and activity levels and different genotypes of
Lp-PLA2, bolstering the hypothesis that there is a sub-
stantial genetic influence on Lp-PLA2 levels. A study of
the Framingham cohort, using 1943 SNPs, suggested that
Lp-PLA2 mass had a multivariable adjusted heritability of
25% and Lp-PLA2 activity had 41% heritability[29].
Among Whites, the Ala379Val coding variant in the
PLA2G7 locus was associated with increased Lp-PLA2
activity, while the Arg92His coding variant was asso-
ciated with decreased activity[22]. Among Japanese indi-
viduals, the Val279Phe SNP also in the PLA2G7 locus,
which is much more prevalent in Japanese than in
Whites, is associated with greatly decreased Lp-PLA2
activity[30]. In fact, people who are homozygous for the
Val279Phe polymorphism have almost no detectable Lp-
PLA2 activity[31,32]. Because of the probable strong
genetic influence on Lp-PLA2 mass and activity levels,
one could hypothesize that the racial variations are due
to genetic differences between races. Our study included
only three SNPs, while the Framingham study revealed
12 SNPs linked with Lp-PLA2 variability[29]. Therefore,
adjusting for only three SNPs in our study was a limited
test of genetic influence on the racial differences in Lp-
PLA2 and did not attenuate the strong association
between race and Lp-PLA2 mass and activity levels.
In addition to the limited number of Lp-PLA2-related
SNPs, another limitation of this analysis is that it is
cross-sectional as we were unable to study whether Lp-
PLA2 level predicts subsequent risk of CHD events dif-
ferentially by race. Before Lp-PLA2 results can be added
to existing CHD risk prediction equations, further evi-
dence is needed to validate its incremental prognostic
value in an ethnically-diverse cohort. Another limitation
is the ability of questionnaires to accurately and fully
Figure 1 Lp-PLA2 mass by race. Afr-Am, African-American, The box
plots ordered by median in descending order. The upper, middle,
and lower line of the shaded box correspond to the 75th percentile,
median, and 25th percentile values. The dots and the whiskers
indicate minimum and maximum values. The dots are values that
are greater than 1.5 times the interquartile range away from the
25th or 75th percentile.
Figure 2 Lp-PLA2 activity by race. Afr-Am, African-American, The
box plots ordered by median in descending order. The upper,
middle, and lower line of the shaded box correspond to the 75th
percentile, median, and 25th percentile values. The dots and the
whiskers indicate minimum and maximum values. The dots are
values that are greater than 1.5 times the interquartile range away
from the 25th or 75th percentile.
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characterize all the lifestyle variations that could explain
the racial differences of Lp-PLA2 mass and activity
levels. For example, there could be other lifestyle factors,
such as diet choices unrelated to fat and carbohydrate
intake, which influence Lp-PLA2 mass and activity levels
but are not captured by the survey. The relatively mod-
est number of non-White participants may also limit
our ability to detect the effects of lifestyle factors.
Lp-PLA2 is viewed as a novel CHD risk marker that
could be used to risk stratify individuals when considering
primary prevention strategies, such as initiating statin ther-
apy or setting lipid treatment goals. Various authors have
suggested using a uniform threshold for Lp-PLA2 mass,
regardless of sex and race, for categorizing risk[1,33]. How-
ever, the results from this study confirm that Lp-PLA2
mass and activity levels vary significantly between Whites
and non-Whites, independent of known biological and life-
style factors. These racial variations could affect the
performance of Lp-PLA2 as a prognostic risk marker. For
example, African-Americans may have lower Lp-PLA2
mass and activity levels than Whites despite having similar
degrees of atherosclerosis and vascular inflammation or
they may simply have less underlying atherosclerotic
disease. In light of the high cardiovascular event rates in
African-Americans, the former possibility seems more
likely. As a result, using the same Lp-PLA2 threshold in
Whites and African-Americans may underestimate risk in
African-Americans compared with Whites.
Conclusions
If Lp-PLA2 mass and activity levels are inherently differ-
ent between races, then these levels may need to be
interpreted differently for various races. Before incorpor-
ating information on Lp-PLA2 mass and activity levels in
assessing cardiovascular risk for individual patients,
additional larger, multi-racial prospective studies are
Table 2 Linear regression models predicting Lp-PLA2 mass (ng/mL)
Race & Sex
(Model 1)
Model 1 + Biological
Covariates





Variables b P-value b P-value b P-value b P-value b P-value
Race†
African-American -55.0 < 0.0001 -50.2 < 0.0001 -57.2 < 0.0001 -49.6 < 0.0001 -47.3 < 0.0001
Hispanic -26.2 0.0016 -25.8 0.0008 -30.1 0.001 -27.7 0.0008 -30.0 0.0004
Asian -47.1 < 0.0001 -45.7 < 0.0001 -45.4 < 0.0001 -43.1 < 0.0001 -42.0 < 0.0001
Female gender‡ -24.2 < 0.0001 -18.5 0.0045 -24.5 < 0.0001 -22.8 < 0.0001 -18.4 0.011
Biological Covariates
Age (years) 2.4 0.0016 2.6 0.0019
Diabetes mellitus -0.0042 0.95 -0.018 0.81
History of hypertension -3.0 0.53 -3.76 0.49
Systolic blood pressure (mmHg) 0.16 0.23 0.14 0.33
Body mass index (kg/m2) -0.46 0.63 -0.063 0.95
Waist circumference (cm) 0.092 0.81 -0.026 0.95
LDL (mg/dL) 0.75 < 0.0001 0.75 < 0.0001
HDL (mg/dL) -0.26 0.094 -0.27 0.11
ADMA§ (μmol/L) 38.8 0.06 33.2 0.14
C-reactive protein (mg/L) 1.1 0.0017 1.1 0.002
Lifestyle/Demographic Covariates
Current smoking 0.012 0.90 0.0058 0.95
Exercise (kCal/kg-day) 0.63 0.40 0.76 0.28
% Calories from saturated fat 0.081 0.94 -0.96 0.38
% Calories from carbohydrates -0.43 0.20 -0.60 0.058
Annual income ≥ $50,000 -0.019 0.74 0.051 0.32
College graduate -0.091 0.086 -0.071 0.15
SNPs
Ala379Val 2.2 0.60 2.5 0.55
Arg92His 11.8 0.0023 11.6 0.0025
Ile198Thr -8.8 0.19 -6.1 0.37
* SNPs, single nucleotide polymorphisms
† Compared to White race
‡ Compared to Male
§ADMA, asymmetric dimethylarginine
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needed to delineate the specific risk associated with dif-
ferent Lp-PLA2 levels within individual racial groups.
Acknowledgements
We thank Themistocles L. Assimes, MD, PhD for statistical advice.
Author details
1Department of Health Research and Policy, Stanford University School of
Medicine, HRP Redwood Building, Stanford, CA 94305-5405 USA. 2Kaiser
Santa Clara Cardiology, Department 348, Kaiser Permanente of Northern
California, 710 Lawrence Expressway, Santa Clara, CA 95051 USA. 3Center for
Health Research, Kaiser Permanente Northwest, 3800 N. Interstate Avenue,
Portland, OR 97227 USA. 4Stanford Prevention Research Center, Stanford
University School of Medicine, Medical School Office Building, 251 Campus
Drive, Stanford, CA 94305-5411 USA. 5Division of Research, Kaiser
Permanente of Northern California, 2000 Broadway, Oakland, CA 94612 USA.
6Department of Epidemiology, Biostatistics, and Medicine, University of
California, San Francisco, 185 Berry Street, Lobby 5, Suite 5700, San Francisco,
CA 94107 USA. 7Cardiovascular Medicine, Stanford University School of
Medicine, 300 Pasteur Drive, Falk Cardiovascular Research Center, Stanford,
CA 94305-5406 USA.
Authors’ contributions
SPF, JMF, CI, ASG, MAH, and TQ conceived of the study. AV, KKL, JMF, SPF,
and CI had input to the statistical analyses. KKL drafted the manuscript. All
authors edited the manuscript, approved the analyses, and read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 28 May 2010 Accepted: 29 June 2011 Published: 29 June 2011
References
1. Corson MA, Jones PH, Davidson MH: Review of the evidence for the
clinical utility of lipoprotein-associated phospholipase A2 as a
cardiovascular risk marker. Am J Cardiol 2008, 101:41F-50F.
2. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F:
Association between lipoprotein-associated phospholipase A2 and
cardiovascular disease: a systematic review. Mayo Clin Proc 2007,
82:159-65.
3. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G,
Sharrett AR: Lipoprotein-associated phospholipase A2, high-sensitivity C-
reactive protein, and risk for incident coronary heart disease in middle-










Variables b P-value b P-value b P-value b P-value b P-value
Race†
African-American -24.7 < 0.0001 -18.5 < 0.0001 -27.0 < 0.0001 -22.8 < 0.0001 -18.0 < 0.0001
Hispanic -10.1 0.009 -10.6 0.0006 -14.4 0.0006 -10.2 0.009 -13.1 0.0001
Asian -12.1 0.003 -14.2 < 0.0001 -10.4 0.018 -11.9 0.004 -13.9 0.0001
Female gender‡ -28.1 < 0.0001 -18.2 < 0.0001 -28.3 < 0.0001 -27.6 < 0.0001 -17.4 < 0.0001
Biological Covariates
Age (years) 1.05 0.0006 1.13 0.0006
Diabetes mellitus -0.057 0.038 -0.067 0.024
History of hypertension -2.38 0.23 -3.65 0.094
Systolic blood pressure (mmHg) -0.0034 0.95 0.0012 0.98
Body mass index (kg/m2) -0.41 0.29 -0.34 0.39
Waist circumference (cm) 0.041 0.79 -0.0066 0.97
LDL (mg/dL) 0.44 < 0.0001 0.45 < 0.0001
HDL (mg/dL) -0.69 < 0.0001 -0.72 < 0.0001
ADMA§ (μmol/L) 23.4 0.0048 23.1 0.012
C-reactive protein (mg/L) -0.23 0.10 -0.22 0.13
Lifestyle/Demographic Covariates
Current smoking 0.035 0.43 0.025 0.49
Exercise (kCal/kg-day) 0.36 0.30 0.38 0.17
% Calories from saturated fat 1.09 0.038 0.047 0.91
% Calories from carbohydrates 0.31 0.045 -0.055 0.66
Annual income ≥ $50,000 -0.023 0.38 0.011 0.60
College graduate -0.0095 0.70 0.014 0.48
SNPs
Ala379Val 1.20 0.55 1.45 0.40
Arg92His -2.06 0.26 -3.75 0.015
Ile198Thr -6.03 0.056 -4.38 0.11
* SNPs, single nucleotide polymorphisms
† Compared to White race
‡ Compared to Male
§ADMA, asymmetric dimethylarginine
Lee et al. BMC Cardiovascular Disorders 2011, 11:38
http://www.biomedcentral.com/1471-2261/11/38
Page 7 of 8
aged men and women in the Atherosclerosis Risk in Communities
(ARIC) study. Circulation 2004, 109:837-42.
4. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C: Lipoprotein-
associated phospholipase A2 adds to risk prediction of incident
coronary events by C-reactive protein in apparently healthy middle-
aged men from the general population: results from the 14-year follow-
up of a large cohort from southern Germany. Circulation 2004,
110:1903-8.
5. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM,
Witteman JC: Lipoprotein-associated phospholipase A2 activity is
associated with risk of coronary heart disease and ischemic stroke: the
Rotterdam Study. Circulation 2005, 111:570-5.
6. Packard CJ, O’Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J,
Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD:
Lipoprotein-associated phospholipase A2 as an independent predictor
of coronary heart disease. West of Scotland Coronary Prevention Study
Group. N Engl J Med 2000, 343:1148-55.
7. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE,
Myerson M, Wu KK, Sharrett AR, Boerwinkle E: Lipoprotein-associated
phospholipase A2, high-sensitivity C-reactive protein, and risk for
incident ischemic stroke in middle-aged men and women in the
Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005,
165:2479-84.
8. Iribarren C: Lipoprotein-Associated Phospholipase A2 and C-Reactive
Protein for Measurement of Inflammatory Risk: Independent or
Complementary? Cardiovascular Risk Reports 2010.
9. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S,
Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C,
Thompson SG, Collins R, Danesh J: Lipoprotein-associated phospholipase
A(2) and risk of coronary disease, stroke, and mortality: collaborative
analysis of 32 prospective studies. Lancet 2010, 375:1536-44.
10. White H, Held C, Stewart R, Watson D, Harrington R, Budaj A, Steg PG,
Cannon CP, Krug-Gourley S, Wittes J, Trivedi T, Tarka E, Wallentin L: Study
design and rationale for the clinical outcomes of the STABILITY Trial
(STabilization of Atherosclerotic plaque By Initiation of darapLadIb
TherapY) comparing darapladib versus placebo in patients with
coronary heart disease. Am Heart J 2010, 160:655-61.
11. Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, Murphy SA, de
Lemos JA: Influence of race and sex on lipoprotein-associated
phospholipase A2 levels: observations from the Dallas Heart Study.
Atherosclerosis 2008, 199:110-5.
12. Fair JM, Kiazand A, Varady A, Mahbouba M, Norton L, Rubin GD, Iribarren C,
Go AS, Hlatky MA, Fortmann SP: Ethnic differences in coronary artery
calcium in a healthy cohort aged 60 to 69 years. Am J Cardiol 2007,
100:981-5.
13. Taylor-Piliae RE, Norton LC, Haskell WL, Mahbouda MH, Fair JM, Iribarren C,
Hlatky MA, Go AS, Fortmann SP: Validation of a new brief physical activity
survey among men and women aged 60-69 years. Am J Epidemiol 2006,
164:598-606.
14. Assimes TL, Knowles JW, Priest JR, Basu A, Borchert A, Volcik KA, Grove ML,
Tabor HK, Southwick A, Tabibiazar R, Sidney S, Boerwinkle E, Go AS,
Iribarren C, Hlatky MA, Fortmann SP, Myers RM, Kuhn H, Risch N,
Quertermous T: A near null variant of 12/15-LOX encoded by a novel
SNP in ALOX15 and the risk of coronary artery disease. Atherosclerosis
2008, 198:136-44.
15. Sydow K, Fortmann SP, Fair JM, Varady A, Hlatky MA, Go AS, Iribarren C,
Tsao PS: Distribution of asymmetric dimethylarginine among 980
healthy, older adults of different ethnicities. Clin Chem 2009, 56:111-20.
16. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB:
Association of lipoprotein-associated phospholipase A2 levels with
coronary artery disease risk factors, angiographic coronary artery
disease, and major adverse events at follow-up. Eur Heart J 2005,
26:137-44.
17. Koenig W, Twardella D, Brenner H, Rothenbacher D: Lipoprotein-associated
phospholipase A2 predicts future cardiovascular events in patients with
coronary heart disease independently of traditional risk factors, markers
of inflammation, renal function, and hemodynamic stress. Arterioscler
Thromb Vasc Biol 2006, 26:1586-93.
18. Blair SN, Haskell WL, P Ho, Paffenbarger RS, Vranizan KM, Farquhar JW,
Wood PD: Assessment of habitual physical activity by a seven-day recall
in a community survey and controlled experiments. Am J Epidemiol 1985,
122:794-804.
19. Sallis JF, Haskell WL, Wood PD, Fortmann SP, Rogers T, Blair SN,
Paffenbarger RS Jr: Physical activity assessment methodology in the Five-
City Project. Am J Epidemiol 1985, 121:91-106.
20. Block G, Hartman AM, Dresser CM, Carroll MD, Gannon J, Gardner L: A
data-based approach to diet questionnaire design and testing. Am J
Epidemiol 1986, 124:453-69.
21. Zakharia F, Basu A, Absher D, Assimes TL, Go AS, Hlatky MA, Iribarren C,
Knowles JW, J Li, Narasimhan B, Sidney S, Southwick A, Meyers RM,
Quertermous T, Risch N, Tang H: Characterizing the admixed African
ancestry of African Americans. Genome Biol 2009, 10:R141.
22. Hoffmann MM, Winkler K, Renner W, Winkelmann BR, Seelhorst U,
Wellnitz B, Boehm BO, Marz W: Genetic variants and haplotypes of
lipoprotein associated phospholipase A2 and their influence on
cardiovascular disease (The Ludwigshafen Risk and Cardiovascular
Health Study). J Thromb Haemost 2009, 7:41-8.
23. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, C Li, Williams DE,
Gregg EW, Bainbridge KE, Saydah SH, Geiss LS: Full accounting of diabetes
and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006.
Diabetes Care 2009, 32:287-94.
24. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M,
Kastarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, Stegmayr B,
Thamm M, Tuomilehto J, Vanuzzo D, Vescio F: Hypertension prevalence
and blood pressure levels in 6 European countries, Canada, and the
United States. JAMA 2003, 289:2363-9.
25. Albert MA, Glynn RJ, Wolfert RL, Ridker PM: The effect of statin therapy on
lipoprotein associated phospholipase A2 levels. Atherosclerosis 2005,
182:193-8.
26. El-Saed A, Sekikawa A, Zaky RW, Kadowaki T, Takamiya T, Okamura T,
Edmundowicz D, Kita Y, Kuller LH, Ueshima H: Association of lipoprotein-
associated phospholipase A2 with coronary calcification among
American and Japanese men. J Epidemiol 2007, 17:179-85.
27. Allison MA, Denenberg JO, Nelson JJ, Natarajan L, Criqui MH: The
association between lipoprotein-associated phospholipase A2 and
cardiovascular disease and total mortality in vascular medicine patients.
J Vasc Surg 2007, 46:500-6.
28. Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD:
Effects of diet and exercise in men and postmenopausal women with
low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J
Med 1998, 339:12-20.
29. Schnabel R, Dupuis J, Larson MG, Lunetta KL, Robins SJ, Zhu Y, Rong J,
Yin X, Stirnadel HA, Nelson JJ, Wilson PW, Keaney JF, Vasan RS, Benjamin EJ:
Clinical and genetic factors associated with lipoprotein-associated
phospholipase A2 in the Framingham Heart Study. Atherosclerosis 2009,
204:601-7.
30. Zhang SY, Shibata H, Karino K, Wang BY, Kobayashi S, Masuda J, Nabika T:
Comprehensive evaluation of genetic and environmental factors
influencing the plasma lipoprotein-associated phospholipase A2 activity
in a Japanese population. Hypertens Res 2007, 30:403-9.
31. Wang T, Karino K, Yamasaki M, Zhang Y, Masuda J, Yamaguchi S, Shiwaku K,
Nabika T: Effects of G994T in the Lp-PLA2 gene on the plasma oxidized
LDL level and carotid intima-media thickness in Japanese: the Shimane
study. Am J Hypertens 2009, 22:742-7.
32. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M:
Correlations between plasma platelet-activating factor acetylhydrolase
(PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a
Japanese population. Atherosclerosis 2000, 150:209-16.
33. Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR,
McConnell JP: Lipoprotein-associated phospholipase A2: review and
recommendation of a clinical cut point for adults. Prev Cardiol 2006,
9:138-43.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2261/11/38/prepub
doi:10.1186/1471-2261-11-38
Cite this article as: Lee et al.: Racial variation in lipoprotein-associated
phospholipase A2 in older adults. BMC Cardiovascular Disorders 2011
11:38.
Lee et al. BMC Cardiovascular Disorders 2011, 11:38
http://www.biomedcentral.com/1471-2261/11/38
Page 8 of 8
